VIENNA, Va., May 1 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex:
CVM) announces that CEL-1000 alone increased the immune response against
hepatitis B antigen, and that the combination of CEL-1000 with MAS-1, a
proprietary water-in-oil adjuvant delivery system owned by Mercia Pharma,
induced highly significant increases in specific anti-HBV (hepatitis B
virus) antibodies. These findings were presented by Dr. Daniel Zimmerman,
Senior Vice President of Research, Cellular Immunology at CEL-SCI at the
10th Annual Conference of the National Foundation for Infectious Diseases
in Baltimore, Maryland.
This new finding with CEL-1000 may have broad application for the
enhancement of immune responses by individuals who have a poor immune
response to vaccinations. It also has application for antigen sparing
(reducing the amount/dose of antigen) required for protective immunity, and
application to biodefense and pandemic settings for anti-infectious
vaccines.
Dr. Zimmerman said, "A good number of people, a great majority of them
middle aged and older men, vaccinated against Hepatitis B fail to generate
high enough levels of antibodies to be considered protected. These
individuals need and deserve a better level of protection."
CEL-1000 has previously been shown to be protective in animal challenge
studies against viruses and unrelated diseases, specifically herpes simplex
virus, viral encephalitis and malaria. CEL-1000 appears to activate innate
(very early stage) and Th1 type (cellular) immune responses to induce a
broad- spectrum protection against infection in animal models. The innate
immune system is generally accepted to be the first line of defense against
infectious agents.
CEL-1000, derived from the beta chain of human MHC-II, is a modified
version of a human immune-based protein known to bind to both human and
mouse immune cells and appears to act by enhancing the host's protective
immune response. More information on CEL-1000 is available at
http://www.cel-sci.com.
CEL-SCI Corporation is developing new immune system based treatments
for cancer and infectious diseases. The Company has operations in Vienna,
Virginia and Baltimore, Maryland. The Company's lead product Multikine(R)
is cleared to enter a global Phase III clinical trial in advanced primary
head and neck cancer patients in the U.S. and Canada. CEL-SCI's other
products, which are currently in pre-clinical stage, have shown protection
against a number of diseases in animal tests and are being tested against
diseases associated with bio-defense and avian flu.
SOURCE CEL-SCI Corporation
 back to top
Related links:
http://www.cel-sci.com
CONTACT:
Gavin de Windt of CEL-SCI Corporation,
+1-703-506-9460
|
